• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

Alcoholic Cirrhosis and Elevated Liver Enzymes: Your Dx?

Article

the dramatic elevation of aminotransferases may be the result of medication toxicity, acute viral hepatitis, or ischemic injury to the liver. Your assessment?

A 68-year-old man with alcoholic cirrhosis presents with worsening confusion. Lab test results are notable for an AST of 3600 U/L and an ALT 4200 U/L. His alkaline phosphatase level is within normal limits and his total bilirubin is 3.1 mg/dL. His INR is 1.4.

Which of the following is the most likely cause of his presentation?

a. Cholangiocarcinoma
b. Acute hepatitis A
c. Alcoholic hepatitis
d. Acetaminophen toxicity

 Please click here for the answer and discussion.

Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Related Content
FDA Approves Simplified Once-Monthly Mirikizumab-mrkz Regimen for Ulcerative Colitis Maintenance Therapy / image credit: ©Waldenmarus/AdobeStock

FDA Approves Simplified Once-Monthly Mirikizumab-mrkz Regimen for Ulcerative Colitis Maintenance Therapy

Sydney Jennings
November 5th 2025
Article

The FDA approves a single monthly injection of mirikizumab-mrkz for ulcerative colitis, enhancing patient convenience and addressing bowel urgency effectively.

Countering Vaccine Misinformation in Clinical Practice with Amesh Adalja, MD: Primary Viewpoints Podcast

Countering Vaccine Misinformation in Clinical Practice with Amesh Adalja, MD: Primary Viewpoints Podcast

Amesh Adalja, MD;Sydney Jennings
August 22nd 2025
Podcast

Infectious disease expert shares strategies for PCPs to counter vaccine myths, navigate policy changes, and build patient trust.

Non-Celiac Gluten/Wheat Sensitivity Affects 1 in 10 Globally, Often with Comorbid IBS

Non-Celiac Gluten/Wheat Sensitivity Affects 1 in 10 Globally, Often with Comorbid IBS

Grace Halsey
October 30th 2025
Article

One in ten adults report NCGWS, frequently coexisting with IBS, anxiety, or depression, suggesting a central role for the gut-brain axis in pathophysiology.

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Sydney Jennings
May 7th 2025
Podcast

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

Investigational Two-Drug HIV Regimen Shows Minimal Impact on Weight and Lipids in Phase 3 Trials / Image credit: ©artegorov3@gmail/AdobeStock

Investigational Two-Drug HIV Regimen Shows Minimal Impact on Weight and Lipids in Phase 3 Trials

Sydney Jennings
October 15th 2025
Article

Merck reveals promising phase 3 results for DOR/ISL, showing minimal impact on weight and lipids in adults with suppressed HIV-1.

FDA Approves Updated Indication Statement for Upadacitinib in Inflammatory Bowel Disease Treatment / Image credit: ©unlimit3d/AdobeStock

FDA Approves Updated Indication Statement for Upadacitinib in Inflammatory Bowel Disease Treatment

Sydney Jennings
October 14th 2025
Article

FDA approves updated indication for upadacitinib in ulcerative colitis and Crohn disease treatment, allowing use after one systemic therapy when TNF blockers are clinically inadvisable.

© 2025 MJH Life Sciences

All rights reserved.